thiamine has been researched along with Diabetic Neuropathies in 49 studies
thiamine(1+) : A primary alcohol that is 1,3-thiazol-3-ium substituted by (4-amino-2-methylpyrimidin-5-yl)methyl, methyl and 2-hydroxyethyl groups at positions 3, 4 and 5, respectively.
Diabetic Neuropathies: Peripheral, autonomic, and cranial nerve disorders that are associated with DIABETES MELLITUS. These conditions usually result from diabetic microvascular injury involving small blood vessels that supply nerves (VASA NERVORUM). Relatively common conditions which may be associated with diabetic neuropathy include third nerve palsy (see OCULOMOTOR NERVE DISEASES); MONONEUROPATHY; mononeuropathy multiplex; diabetic amyotrophy; a painful POLYNEUROPATHY; autonomic neuropathy; and thoracoabdominal neuropathy. (From Adams et al., Principles of Neurology, 6th ed, p1325)
| Excerpt | Relevance | Reference |
|---|---|---|
| " Nonetheless, pain intensity reduction is achieved with 50% of the minimum required gabapentin dose alone (800 to 1600 mg/d) in classic NDD trials." | 9.22 | Clinical Trial Assessing the Efficacy of Gabapentin Plus B Complex (B1/B12) versus Pregabalin for Treating Painful Diabetic Neuropathy. ( Aguilar Navarro, S; Mimenza Alvarado, A, 2016) |
| " Nonetheless, pain intensity reduction is achieved with 50% of the minimum required gabapentin dose alone (800 to 1600 mg/d) in classic NDD trials." | 5.22 | Clinical Trial Assessing the Efficacy of Gabapentin Plus B Complex (B1/B12) versus Pregabalin for Treating Painful Diabetic Neuropathy. ( Aguilar Navarro, S; Mimenza Alvarado, A, 2016) |
| "Forty-five diabetes patients with painful peripheral polyneuropathy were enrolled in a 3-month observational study comparing the therapeutic efficacy of Milgamma tablets (50 mg benfothiamine and 0." | 5.08 | Therapeutic efficacy of "Milgamma" in patients with painful diabetic neuropathy. ( Mincheva, L; Mitkov, M; Pavlova, M; Simeonov, S; Troev, D, 1997) |
| " Currently, there are only few pathogenetically oriented pharmacotherapies for DSPN, one of which is benfotiamine, a prodrug of thiamine with a high bioavailability and favourable safety profile." | 3.11 | BOND study: a randomised double-blind, placebo-controlled trial over 12 months to assess the effects of benfotiamine on morphometric, neurophysiological and clinical measures in patients with type 2 diabetes with symptomatic polyneuropathy. ( Al-Hasani, H; Bönhof, GJ; Herder, C; Icks, A; Knebel, B; Kuss, O; Reule, C; Roden, M; Sipola, G; Strassburger, K; Strom, A; Wollmann, JC; Ziegler, D, 2022) |
| "In people with Type 2 diabetes and markedly impaired fasting flow-mediated dilatation, a mixed test meal does not further deteriorate flow-mediated dilatation or variables of microvascular or autonomic nervous function." | 2.78 | A randomized, double-blind, crossover, placebo-controlled trial of 6 weeks benfotiamine treatment on postprandial vascular function and variables of autonomic nerve function in Type 2 diabetes. ( Pop, A; Stirban, A; Tschoepe, D, 2013) |
| "165 patients with symmetrical, distal diabetic polyneuropathy were randomised to one of three treatment groups entering the wash-out phase and 133/124 patients were analysed in the ITT/PP analysis: Benfotiamine 600 mg per day (n=47/43), benfotiamine 300 mg per day (n=45/42) or placebo (n=41/39)." | 2.73 | Benfotiamine in diabetic polyneuropathy (BENDIP): results of a randomised, double blind, placebo-controlled clinical study. ( Achenbach, U; Bretzel, RG; Federlin, K; Gaus, W; Stracke, H, 2008) |
| " The form of administration (ampoules, dragées), dosage and duration of treatment were left to the individual care-providing physician." | 2.67 | [Therapy of neuropathies with a vitamin B combination. Symptomatic treatment of painful diseases of the peripheral nervous system with a combination preparation of thiamine, pyridoxine and cyanocobalamin]. ( Eckert, M; Schejbal, P, 1992) |
| "Thiamine is a water-soluble vitamin, rapidly expelled from the body, with no issues of over-dosage or accumulation; unfortunately, it is non-patentable, and neither industry nor independent donors are interested in investing in large-scale randomized controlled clinical trials to investigate its potential in diabetes and its complications." | 1.62 | Thiamine and diabetes: back to the future? ( Beltramo, E; Mazzeo, A; Porta, M, 2021) |
| " The dosage plan for hospitalized patients differed from that for outpatients." | 1.26 | Influence of neurotropic vitamins on the nerve conduction velocity in diabetic neuropathy. ( Tong, HI, 1980) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 17 (34.69) | 18.7374 |
| 1990's | 9 (18.37) | 18.2507 |
| 2000's | 10 (20.41) | 29.6817 |
| 2010's | 10 (20.41) | 24.3611 |
| 2020's | 3 (6.12) | 2.80 |
| Authors | Studies |
|---|---|
| Bönhof, GJ | 1 |
| Sipola, G | 1 |
| Strom, A | 1 |
| Herder, C | 1 |
| Strassburger, K | 1 |
| Knebel, B | 1 |
| Reule, C | 1 |
| Wollmann, JC | 1 |
| Icks, A | 1 |
| Al-Hasani, H | 1 |
| Roden, M | 1 |
| Kuss, O | 1 |
| Ziegler, D | 2 |
| Stirban, OA | 1 |
| Zeller-Stefan, H | 1 |
| Schumacher, J | 1 |
| Gaus, W | 2 |
| Schuerholz, T | 1 |
| Pop-Busui, R | 1 |
| Beltramo, E | 1 |
| Mazzeo, A | 1 |
| Porta, M | 1 |
| Várkonyi, T | 2 |
| Körei, A | 1 |
| Putz, Z | 1 |
| Martos, T | 1 |
| Keresztes, K | 1 |
| Lengyel, C | 1 |
| Nyiraty, S | 1 |
| Stirban, A | 2 |
| Jermendy, G | 1 |
| Kempler, P | 6 |
| Zhuravleva, MV | 1 |
| Shikh, EV | 1 |
| Makhova, AA | 1 |
| Pop, A | 1 |
| Tschoepe, D | 1 |
| Sergienko, VA | 1 |
| Segin, VB | 1 |
| Samir, A | 1 |
| Sergienko, AA | 1 |
| Zhu, Z | 1 |
| Varadi, G | 1 |
| Carter, SG | 1 |
| Mimenza Alvarado, A | 1 |
| Aguilar Navarro, S | 1 |
| Winkler, G | 2 |
| SHUMAN, CR | 1 |
| GILPIN, SF | 1 |
| BELLODI, G | 1 |
| KUNZ, O | 1 |
| MEDURI, D | 1 |
| WADA, M | 1 |
| NAKAO, K | 1 |
| KITO, S | 2 |
| TAKASU, T | 1 |
| TASAKA, S | 1 |
| REDFERN, WE | 1 |
| BEBIN, J | 1 |
| EISENBREY, AB | 1 |
| Haupt, E | 1 |
| Ledermann, H | 1 |
| Köpcke, W | 1 |
| Nakamura, J | 1 |
| Medvedeva, LA | 1 |
| Gnezdilov, AV | 1 |
| Zagorul'ko, OI | 1 |
| Syrovegin, AV | 1 |
| Samoĭlova, NV | 1 |
| Slashchuk, IuI | 1 |
| Wernicke, JF | 1 |
| Wang, F | 1 |
| Pritchett, YL | 1 |
| Smith, TR | 1 |
| Raskin, J | 1 |
| D'Souza, DN | 1 |
| Iyengar, S | 1 |
| Chappell, AS | 1 |
| Stracke, H | 2 |
| Achenbach, U | 1 |
| Federlin, K | 2 |
| Bretzel, RG | 1 |
| Nowak, S | 1 |
| Rieder, HP | 1 |
| Berger, W | 1 |
| Fridrich, R | 1 |
| Aksaranugraha, S | 1 |
| Chandraprasert, S | 1 |
| Niamjinda, T | 1 |
| Hobara, R | 1 |
| Ozawa, K | 1 |
| Okazaki, M | 1 |
| Yasuhara, H | 1 |
| Tong, HI | 1 |
| Straub, RH | 1 |
| Rokitzki, L | 1 |
| Schumacher, T | 1 |
| Hillmann, C | 1 |
| Palitzsch, KD | 1 |
| Schölmerich, J | 1 |
| Lindemann, A | 1 |
| Abbas, ZG | 1 |
| Swai, AB | 1 |
| Simeonov, S | 1 |
| Pavlova, M | 1 |
| Mitkov, M | 1 |
| Mincheva, L | 1 |
| Troev, D | 1 |
| Sadekov, RA | 1 |
| Danilov, AB | 1 |
| Veĭn, AM | 1 |
| Pál, B | 1 |
| Nagybéganyi, E | 1 |
| Ory, I | 1 |
| Porochnavec, M | 1 |
| Balabolkin, MI | 1 |
| Kreminskaia, VM | 1 |
| Eckert, M | 1 |
| Schejbal, P | 1 |
| Ishii, N | 1 |
| Shirai, M | 1 |
| Miyoshi, T | 1 |
| Goto, I | 1 |
| Bedi, HK | 1 |
| Devpura, JC | 1 |
| Kumar, B | 1 |
| Bedi, T | 1 |
| Klein, W | 1 |
| Kuzuya, K | 1 |
| Irino, J | 1 |
| Tanaka, S | 1 |
| Shiraki, T | 1 |
| Yamaguchi, K | 1 |
| Muro, T | 1 |
| Tomonaga, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Multicenter, Randomized, Open-label, Parallel Group, Phase IV Study to Compare the Efficacy and Safety of Gabapentin/B-complex Versus Pregabalin in the Management of Diabetic Peripheral Neuropathic Pain[NCT01364298] | Phase 4 | 353 participants (Actual) | Interventional | 2011-04-30 | Completed | ||
| A Randomized Double Blinded Pilot Study of Oral Thiamine in the Symptomatic Treatment of Painful Diabetic Peripheral Neuropathy[NCT00279266] | 0 participants (Actual) | Interventional | 2006-01-31 | Withdrawn (stopped due to inadequate recruitment) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
An adverse event (AE) is defined as any untoward medical occurrence in the form of signs, symptoms, abnormal laboratory findings, or diseases that emerges or worsens relative to Baseline during a clinical study with an investigational medicinal product (IMP), regardless of causal relationship and even if no IMP has been administered. (NCT01364298)
Timeframe: Day 7 up to Day 84 (+7 days)
| Intervention | participants (Number) |
|---|---|
| Gabapentin/B-complex | 80 |
| Pregabalin | 93 |
"POMS is a rating scale, which comprises of 65 items that are evaluated in a 0-4 scale, where 0 means not at all and 4 extremely. The scores for the 65 items are added in various combinations to throw six validated factors which are used to calculate total POMS score: (tension-anxiety) + (depression-dejection) + (anger-hostility)+ (fatigue-Inertia) + (confusion-bewilderment) - (vigor-activity). Score range (-40 to 192). Score -40 denotes the best score and score 192 denotes the worst score." (NCT01364298)
Timeframe: Day 84 (Week 12)
| Intervention | units on a scale (Mean) |
|---|---|
| Gabapentin/B-complex | 1.3 |
| Pregabalin | 3.4 |
An average NPIS pain score (daily average records of the past seven days) was evaluated. Numeric pain intensity scale (NPIS) is a 11-point scale, with 0 representing no pain and 10 representing the worst possible pain. The participants were asked to mark the number that best represents the current level of pain they have experienced during the previous 24 hours. Change from baseline data has been calculated as value at baseline minus value at Day 84. (NCT01364298)
Timeframe: Baseline and Day 84 (Week 12)
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline (n=147, 123) | Change at Day 84 (n=146, 122) | |
| Gabapentin/B-complex | 6.7 | 3.905 |
| Pregabalin | 6.8 | 4.260 |
The LANSS scale score is 7-item pain scale that consists of grouped sensory description and sensory examination with simple scoring system. Evaluations in two main areas: pain and sensorial exploration. The first 5 questions asks for presence of unpleasant skin sensations (pricking, tingling, pins and needles), appearance of skin (mottled, red, or pink), increased sensitivity of skin to touch, sudden bursts of electric shock sensations, and hot or burning skin sensations. Last 2 questions involve sensory testing for the presence of allodynia and altered pinprick threshold. Different numbers of points, relative to their significance to neuropathic pain, are given to positive answers for maximum of 24 points. A score less than 12 makes unlikely that participant's symptoms are neuropathic in nature, whereas score more than 12 make neuropathic mechanisms likely to be contributing to participant's pain. Change from baseline data has been calculated as value at baseline minus value at Day 84. (NCT01364298)
Timeframe: Baseline and Day 84 (Week 12)
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline (n=147, 123) | Change at Day 84 (n=146, 122) | |
| Gabapentin/B-complex | 16.2 | 8.082 |
| Pregabalin | 15.8 | 6.967 |
VAS is used to rate the pain as per 10 centimeter (cm) line. The pain intensity score ranges from '0=no pain' to '10=worst possible pain'. Change from baseline data has been calculated as value at baseline minus value at Day 84. (NCT01364298)
Timeframe: Baseline and Day 84 (Week 12)
| Intervention | centimeter (Mean) | |
|---|---|---|
| Baseline (n=147, 123) | Change at Day 84 (n=146, 122) | |
| Gabapentin/B-complex | 7.0 | 4.182 |
| Pregabalin | 7.1 | 4.529 |
CGIC is an assessment that the physician performs to assess the participant's global change in health condition from start of the study on a 7-point scale (1 = extremely improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse 6 = much worse, 7 = extremely worse). (NCT01364298)
Timeframe: Baseline and Day 84 (Week 12)
| Intervention | participants (Number) | ||
|---|---|---|---|
| Health: extremely improved | Health: much improved | Health: minimally improved | |
| Gabapentin/B-complex | 55 | 79 | 11 |
| Pregabalin | 47 | 69 | 6 |
GIPC is an assessment that the participant's global change in health condition from start of the study on a 7-point scale (1 = extremely improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse 6 = much worse, 7 = extremely worse). (NCT01364298)
Timeframe: Baseline and Day 84 (Week 12)
| Intervention | participants (Number) | ||
|---|---|---|---|
| Health: extremely improved | Health: much improved | Health: minimally improved | |
| Gabapentin/B-complex | 62 | 73 | 10 |
| Pregabalin | 47 | 65 | 10 |
NPIS is a 11-point scale, with 0 representing no pain and 10 representing the worst possible pain. The participants were asked to mark the number that best represents the current level of pain they have experienced during the previous 24 hours. (NCT01364298)
Timeframe: Baseline and Day 84 (Week 12)
| Intervention | percentage of participants (Number) | |
|---|---|---|
| At least 30% improvement | At least 50% improvement | |
| Gabapentin/B-complex | 76.9 | 66.0 |
| Pregabalin | 85.4 | 72.4 |
Sleep evaluation was performed by assessing number of participants who fell asleep in a particular pre-specified range of time duration, that is, 0-15 minutes, 16-30 minutes, 31-45 minutes, 46-60 minutes and greater than 60 minutes at Day 84 (Week 12). (NCT01364298)
Timeframe: Day 84 (Week 12)
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| 0 to 15 minutes | 16 to 30 minutes | 31 to 45 minutes | 46 to 60 minutes | Greater than 60 minutes | |
| Gabapentin/B-complex | 85 | 33 | 13 | 8 | 8 |
| Pregabalin | 72 | 33 | 12 | 4 | 2 |
6 reviews available for thiamine and Diabetic Neuropathies
| Article | Year |
|---|---|
Advances in the management of diabetic neuropathy.
Topics: Adjuvants, Immunologic; Amines; Anticonvulsants; Antidepressive Agents; Antioxidants; Cardiovascular | 2017 |
[A relationship between analgesic and neurotropic effects by the example of milgamma].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Biotransformation; Cytochrome P-450 Enzyme System; Diabetic | 2012 |
[Pathomechanism of diabetic neuropathy: background of the pathogenesis-oriented therapy].
Topics: Adjuvants, Immunologic; Antioxidants; Blood Vessels; Diabetic Neuropathies; Hexosamines; Humans; Oxi | 2010 |
[Treatment of neuropathies].
Topics: Adjuvants, Immunologic; Capsaicin; Diabetic Neuropathies; Diagnosis, Differential; Humans; Liver Dis | 2004 |
[Development of therapeutic agents for diabetic neuropathies].
Topics: Aldehyde Reductase; Antioxidants; C-Peptide; Diabetic Neuropathies; Drug Design; Enzyme Inhibitors; | 2005 |
Diabetic neuropathy: new strategies for treatment.
Topics: Aldehyde Reductase; Amines; Analgesics; Anticonvulsants; Antidepressive Agents; Antioxidants; Cycloh | 2008 |
14 trials available for thiamine and Diabetic Neuropathies
| Article | Year |
|---|---|
BOND study: a randomised double-blind, placebo-controlled trial over 12 months to assess the effects of benfotiamine on morphometric, neurophysiological and clinical measures in patients with type 2 diabetes with symptomatic polyneuropathy.
Topics: Diabetes Mellitus, Type 2; Diabetic Neuropathies; Double-Blind Method; Humans; Polyneuropathies; Qua | 2022 |
Treatment with benfotiamine in patients with diabetic sensorimotor polyneuropathy: A double-blind, randomized, placebo-controlled, parallel group pilot study over 12 months.
Topics: Diabetes Mellitus; Diabetic Neuropathies; Double-Blind Method; Humans; Pilot Projects; Polyneuropath | 2020 |
A randomized, double-blind, crossover, placebo-controlled trial of 6 weeks benfotiamine treatment on postprandial vascular function and variables of autonomic nerve function in Type 2 diabetes.
Topics: Adult; Aged; Antioxidants; Autonomic Pathways; Biomarkers; Blood Glucose; Cross-Over Studies; Diabet | 2013 |
Clinical Trial Assessing the Efficacy of Gabapentin Plus B Complex (B1/B12) versus Pregabalin for Treating Painful Diabetic Neuropathy.
Topics: Adolescent; Adult; Aged; Amines; Cyclohexanecarboxylic Acids; Diabetic Neuropathies; Drug Combinatio | 2016 |
Benfotiamine in the treatment of diabetic polyneuropathy--a three-week randomized, controlled pilot study (BEDIP study).
Topics: Adjuvants, Immunologic; Adolescent; Adult; Aged; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type | 2005 |
[Neurometabolic therapy of diabetic neuropathy].
Topics: Adjuvants, Immunologic; Analgesics, Non-Narcotic; Antioxidants; Blood Glucose; Carbamazepine; Diabet | 2006 |
An open-label 52-week clinical extension comparing duloxetine with routine care in patients with diabetic peripheral neuropathic pain.
Topics: Acetaminophen; Amitriptyline; Analgesics; Carbamazepine; Diabetes Complications; Diabetic Neuropathi | 2007 |
Benfotiamine in diabetic polyneuropathy (BENDIP): results of a randomised, double blind, placebo-controlled clinical study.
Topics: Adjuvants, Immunologic; Adult; Aged; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic | 2008 |
A benfotiamine-vitamin B combination in treatment of diabetic polyneuropathy.
Topics: Administration, Oral; Aged; Capsules; Diabetic Neuropathies; Double-Blind Method; Drug Combinations; | 1996 |
Evaluation of the efficacy of thiamine and pyridoxine in the treatment of symptomatic diabetic peripheral neuropathy.
Topics: Analysis of Variance; Diabetic Neuropathies; Diet Surveys; Double-Blind Method; Drug Monitoring; Dru | 1997 |
Therapeutic efficacy of "Milgamma" in patients with painful diabetic neuropathy.
Topics: Adult; Aged; Diabetic Neuropathies; Female; Humans; Male; Middle Aged; Pain; Thiamine; Vitamin B 12; | 1997 |
[Diabetic polyneuropathy treatment by milgamma-100 preparation].
Topics: Adult; Chelating Agents; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Drug Therapy, Combination | 1998 |
Effectiveness of different benfotiamine dosage regimens in the treatment of painful diabetic neuropathy.
Topics: Adult; Aged; Blood Glucose; Chelating Agents; Cholesterol; Diabetic Neuropathies; Female; Glycated H | 1999 |
[Therapy of neuropathies with a vitamin B combination. Symptomatic treatment of painful diseases of the peripheral nervous system with a combination preparation of thiamine, pyridoxine and cyanocobalamin].
Topics: Diabetic Neuropathies; Drug Combinations; Female; Humans; Male; Middle Aged; Neuralgia; Neurologic E | 1992 |
29 other studies available for thiamine and Diabetic Neuropathies
| Article | Year |
|---|---|
Thiamine and diabetes: back to the future?
Topics: Animals; Diabetes Complications; Diabetes Mellitus; Diabetic Nephropathies; Diabetic Neuropathies; H | 2021 |
[The effect of long-chain polyunsaturated higher ω-3 fatty acids, benfotiamine and α-lipoic acid on the lipid metabolism in patients with diabetes mellitus type 2 and cardiovascular autonomic neuropathy].
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; D | 2013 |
Pharmacokinetics of the transdermal delivery of benfotiamine.
Topics: Administration, Cutaneous; Animals; Diabetic Neuropathies; Drug Delivery Systems; Guinea Pigs; Male; | 2016 |
[Treatment of neuropathies].
Topics: Adjuvants, Immunologic; Adrenergic Uptake Inhibitors; Amines; Analgesics; Antioxidants; Capsaicin; C | 2010 |
[Diabetic neuropathies and angiopathies. Compensating for thiamine deficiency].
Topics: Adjuvants, Immunologic; Diabetic Angiopathies; Diabetic Neuropathies; Humans; Thiamine; Thiamine Def | 2010 |
[Prevention of complications in diabetes mellitus. Interdisciplinary collaboration to control sequelae].
Topics: Adjuvants, Immunologic; Animals; Cooperative Behavior; Cross-Sectional Studies; Diabetes Complicatio | 2011 |
Diabetic neuropathy: controlled therapeutic trials.
Topics: Adenosine Triphosphate; Diabetes Complications; Diabetic Neuropathies; Humans; Liver Extracts; Nervo | 1954 |
[ON THE RATIONALITY OF THE HYDROXYCOBALAMINE-THIAMINE MONOPHOSPHORIC ESTER COMBINATION IN TREATMENT].
Topics: Diabetes Mellitus; Diabetic Neuropathies; Geriatrics; Hepatitis; Hepatitis A; Humans; Hydroxocobalam | 1963 |
[TREATMENT OF DIABETIC NEURITIS WITH LIPOPHILIC VITAMIN B1 PREPARATION].
Topics: Diabetes Mellitus; Diabetic Neuropathies; Humans; Neuritis; Thiamine | 1964 |
[ASSOCIATION OF 2 ANTIDIABETIC DRUGS FOR ORAL USE WITH AMP, THIAMINE AND VITAMIN B 12 IN THE TREATMENT OF DIABETIC POLYNEURITIS].
Topics: Adenine Nucleotides; Adenosine Monophosphate; Blood Proteins; Cholesterol; Diabetic Neuropathies; Gl | 1964 |
[DIAGNOSIS OF DIABETIC NEUROPATHIES. CLINICAL ASPECTS].
Topics: Autonomic Nervous System Diseases; Diabetic Neuropathies; Fatigue; Humans; Hypoglycemic Agents; Insu | 1964 |
[DIABETIC NEUROPATHIES AND THEIR TREATMENT].
Topics: Diabetic Neuropathies; Diagnosis; Liver Extracts; Pantothenic Acid; Pathology; Physiology; Procaine; | 1964 |
NEUROPATHY OF DIABETES MELLITUS.
Topics: Diabetes Mellitus; Diabetic Neuropathies; Drug Therapy; Hematinics; Humans; Pathology; Peripheral Ne | 1965 |
[Oral benfotiamine therapy. Thus you protect the nerves of diabetic patients].
Topics: Administration, Oral; Controlled Clinical Trials as Topic; Diabetes Mellitus, Type 1; Diabetes Melli | 2004 |
Benfotiamine. Monograph.
Topics: Alcoholic Neuropathy; Diabetic Angiopathies; Diabetic Nephropathies; Diabetic Neuropathies; Humans; | 2006 |
[Clinical observations on therapeutic application of dithiopropylothiamine].
Topics: Diabetic Neuropathies; Humans; Neuralgia; Pain; Thiamine | 1967 |
[Vitamin status in diabetic neuropathy (thiamine, riboflavin, pyridoxin, cobalamin and tocopherol)].
Topics: Diabetes Complications; Diabetes Mellitus; Diabetic Neuropathies; Diabetic Retinopathy; Female; Huma | 1980 |
The correlation between the activation coefficient of erythrocyte transketolase activity and diabetic neuropathy.
Topics: Adult; Diabetic Neuropathies; Electrodiagnosis; Enzyme Activation; Erythrocytes; Humans; Median Nerv | 1982 |
Relationship between thiamine and glucose levels in diabetes mellitus.
Topics: Animals; Blood Glucose; Diabetes Mellitus; Diabetic Neuropathies; Humans; Male; Rabbits; Thiamine | 1981 |
Influence of neurotropic vitamins on the nerve conduction velocity in diabetic neuropathy.
Topics: Diabetic Neuropathies; Female; Humans; Male; Middle Aged; Neural Conduction; Pyridoxine; Thiamine; V | 1980 |
[Patients with type-II diabetes mellitus and neuropathy have no deficiency of vitamins A, E, beta-carotene, B1, B2, B6, B12 and folic acid].
Topics: Aged; Avitaminosis; beta Carotene; Carotenoids; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Fe | 1993 |
[The effectiveness of the neurotropic agents: benfotiamin combinations].
Topics: Adjuvants, Immunologic; Diabetic Neuropathies; Humans; Thiamine | 1995 |
[Diabetic neuropathy].
Topics: Acupuncture Therapy; Adjuvants, Immunologic; Antioxidants; Combined Modality Therapy; Diabetic Neuro | 2000 |
[Diabetic impotence].
Topics: Alprostadil; Diabetes Complications; Diabetic Angiopathies; Diabetic Neuropathies; Diagnosis, Differ | 1991 |
Serial in vivo determinations of nerve conduction velocity in rat tails. Physiological and pathological changes.
Topics: Animals; Body Temperature; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Disease Models, A | 1973 |
A study of pyruvate metabolism in peripheral neuropathy and response to vitamin B 1 therapy.
Topics: Adolescent; Adult; Diabetic Neuropathies; Female; Humans; Male; Middle Aged; Peripheral Nervous Syst | 1971 |
[Diabetic neuropathy].
Topics: Aged; Diabetes Mellitus; Diabetic Neuropathies; Humans; Middle Aged; Thiamine; Thioctic Acid | 1969 |
[Effect of dicethiamine hydrochloride on diabetic neuropathies].
Topics: Adult; Aged; Diabetic Neuropathies; Female; Humans; Male; Middle Aged; Thiamine | 1968 |
[Neuromuscular disorders in diabetes mellitus].
Topics: Adolescent; Adult; Aged; Child; Diabetic Neuropathies; Electromyography; Female; Humans; Male; Middl | 1968 |